硫酸羟氯喹的临床药理学研究进展

Advances of the clinical pharmacology of hydroxychloroquine sulfate

新型冠状病毒肺炎(coronavirus disease-19,COVID-19)的感染人数不断增加,医疗形势十分严峻,潜在治疗药物、疫苗与干细胞替换方法不断涌现,寻找特效的治疗药物和最佳的治疗方案迫在眉睫。氯喹在小样本临床试验中展现了优于洛匹那韦/利托那韦(克力芝)的临床抗病毒治疗效果。鉴于羟氯喹具有与氯喹相似的作用机制,且在治疗疟疾和免疫性疾病的临床实践中的安全性比氯喹更好,因此我研究室现针对羟氯喹的临床药理学特征进行综述,希望从临床药理学与定量药理学角度为羟氯喹临床验证提供理论支持。

As the number of novel coronavirus disease(COVID-19)continues to increase,the medical situation is still critical,and potential therapeutic drugs,vaccines and stem cell replacement approaches are emerging.Chloroquine has shown better clinical antiviral efficacy than lopinavir/litonavir(clazidine)in clinical trials of small sample size.Since pharmacological action mechanism of hydroxychloroquine is similar with chloroquine and hydroxychloroquine is safer than chloroquine in the treatment of malaria and immunological diseases,the clinical pharmacology characteristics of hydroxychloroquine was reviewed,hoping to provide theoretical support for clinical effect verification of hydroxychloroquine from the perspective of clinical pharmacology and quantitative pharmacology.